## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.47 indicates fundamental undervaluation. Quality metrics strong (ROE 37%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-7.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($77.82)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Solventum Corp. stock falls Tuesday, underperforms market**
- Source: MarketWatch | 20251209T210835 | Neutral | Relevance: 99%
-  Solventum Corp. (SOLV) saw its stock fall by 3.01% on Tuesday, closing at $80.11. This decline occurred during a generally negative trading session where the S&P 500 Index dropped 0.09% and the Dow Jones Industrial Average fell 0.38%. This marks the second consecutive day of losses for Solventum Corp.

**2. Solventum (SOLV): Reassessing Valuation After a Strong Year-to-Date Rally and Recent Pullback**
- Source: Yahoo Finance | 20251210T051100 | Somewhat-Bullish | Relevance: 99%
-  Solventum (SOLV) has seen a significant 22% year-to-date rally, despite a recent pullback, outperforming the broader market. The article questions whether the stock, currently trading near analyst targets with modest earnings growth, still offers an attractive discount or if its future growth is already priced in. Simply Wall St's narrative suggests Solventum is 3.2% undervalued, with a fair value of $82.80, attributing potential upside to strategic optimization, a strong balance sheet for M&A, and improving margins.

**3. Solventum Corp. stock falls Tuesday, underperforms market**
- Source: MarketWatch | 20251209T213215 | Neutral | Relevance: 98%
-  Solventum Corp. (SOLV) shares declined by 3.01% on Tuesday, closing at $80.11. This underperformance occurred during a broader market downturn where the S&P 500 Index fell 0.09% and the Dow Jones Industrial Average fell 0.38%. This marks the second consecutive day of losses for Solventum Corp.

**4. Should You Add Solventum Corp (SOLV) to Your Portfolio?**
- Source: Insider Monkey | 20251210T083800 | Somewhat-Bullish | Relevance: 98%
-  Pzena Investment Management initiated a new position in Solventum Corporation (NYSE: SOLV) in Q3 2025, viewing it as an attractive opportunity despite concerns about its separation from 3M. The healthcare company's one-month return was 8.51%, and shares gained 13.65% over the last 52 weeks, closing at $80.11 on December 09, 2025. While hedge fund interest in SOLV is growing, Pzena's letter suggests that some AI stocks may offer even greater potential for returns.

**5. Solventum Corporation (SOLV): A Bull Case Theory**
- Source: Finviz | 20251209T200815 | Bullish | Relevance: 98%
- This article summarizes a bull thesis on Solventum Corporation (SOLV), a healthcare company recently spun off from 3M. Despite initial high debt, the company has deleveraged significantly through asset sales and is now positioned for a turnaround under strong leadership. The thesis highlights attractive valuation, clear growth targets, and a favorable risk-reward profile for patient investors, while acknowledging risks like potential PFAS litigation.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | BTIG | $100 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | BTIG | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-7.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 12.9x stretched relative to 5% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.2B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 12.9 |
| Current P/E | 13.6 |
| YoY Growth | 5.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.5% to -1.9% (-7.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.9pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.86% (CS: 41) | Neutral |
| RSI_14 | 57.1 | Neutral |
| MACD Histogram | -0.49 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.086x | Above |
| vs SMA200 | 1.115x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $81.90
- **Stop Loss:** $77.82 (5.0% risk)
- **Target:** $90.06 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 122
- **Position Value:** $9,991.80
- **Portfolio %:** 9.99%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*